Search Results - "Mavacamten"

Managing drug–drug interactions with mavacamten : A focus on combined use of antiarrhythmic drugs and anticoagulants

Ricci, Fabrizio, Molinari, Lorenzo V., Mansour, Davide, Galanti, Kristian, Vagnarelli, Fabio, Renda, Giulia, Gallina, Sabina, Owens, Anjali, Luzum, Jasmine A., Olivotto, Iacopo, Khanji, Mohammed Y., Chahal, Anwar A.

Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study

Tian, Zhuang^Aff1, Li, Xiaoyan^Aff2, Li, Liwen^Aff3, Zhang, Qing, Wang, Jian’an, Shi, Yunqi, Peng, Daoquan, Yang, Ping, Ma, Wei, Wang, Fang, Jin, Wei, Cheng, Xiang, Chen, Yu-Mao, Zhong, Yue, Barrett, Yu Chen, Zheng, Jing, Zhang, Shuyang^{Aff1, IDs40119025004095_cor1}

Mavacamten Inhibits the Effect of the N-Terminal Fragment of Cardiac Myosin-Binding Protein C with the L352P Mutation on the Actin–Myosin Interaction at Low Calcium Concentrations

Kochurova, Anastasia M., Beldiia, Evgenia A., Antonets, Julia Y., Nefedova, Victoria V., Ryabkova, Natalia S.^{Aff3, Aff4}, Katrukha, Ivan A.^{Aff3, Aff4}, Bershitsky, Sergey Y., Matyushenko, Alexander M., Kopylova, Galina V., Shchepkin, Daniil V.^{Aff1, IDS0006297924604131_cor1}

The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review

Othman, Leen, Koskina, Lida, Huerta, Nicholas, Rao, Shiavax J.^{Aff2, IDs1074102410476w_cor1}

Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury

Yusof, Nur Liyana Mohammed^{Aff1, Aff2}, Yellon, Derek M., Davidson, Sean M.^{Aff1, IDs10557024076630_cor1}

Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy.

Garcia-Pavia, Pablo, Oręziak, Artur, Masri, Ahmad, Barriales-Villa, Roberto, Abraham, Theodore, Owens, Anjali, Jensen, Morten, Wojakowski, Wojciech, Seidler, Tim, Hagege, Albert, Lakdawala, Neal, Wang, Andrew, Wheeler, Matthew, Choudhury, Lubna, Balaratnam, Ganesh, Shah, Ashish, Fox, Shawna, Hegde, Sheila, Olivotto, Iacopo

application/pdf

Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period

Becker, Finn^{Aff1, Aff2, Aff3}, Novotny, Julia^{Aff1, Aff2}, Jansen, Nadine, Clauß, Sebastian^{Aff1, Aff2, Aff3, Aff4, Aff5}, Möller-Dyrna, Florian, Specht, Birge, Orban, Madeleine^{Aff1, Aff2}, Massberg, Steffen^{Aff1, Aff2, Aff5}, Kääb, Stefan^{Aff1, Aff2, Aff3, Aff5, IDs0039202402544w_cor9}, Reichart, Daniel^{Aff1, Aff2, Aff3, Aff5}

An ALPK3 truncation variant causing autosomal dominant hypertrophic cardiomyopathy is partially rescued by mavacamten

Lisa Leinhos, Paul Robinson, Giulia Poloni, Sophie Broadway-Stringer, Julia Beglov, Adam B. Lokman, Gillian Douglas, Sajjad Nuthay, Oveena Fonseka, Manuel Schmid, Evie Singer, Charlotte Hooper, Kate Thomson, Richard D. Bagnall, Jodie Ingles, Christopher Semsarian, Elizabeth Ormondroyd, Christopher N. Toepfer, Benjamin Davies, Charles Redwood, Hugh Watkins, Katja Gehmlich

electronic resource

View item

Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre

Zaid Abood, Muhammad Fuad Jan, Muddasir Ashraf, Stacie Kroboth, Heather Sanders, McKenzie Schweitzer, Amanda Misicka, Emily Ollerman, Arshad Jahangir, Patrycja Galazka, Abdul Jamil Tajik

electronic resource

View item

Patient-Level Artificial Intelligence–Enhanced Electrocardiography in Hypertrophic Cardiomyopathy Longitudinal Treatment and Clinical Biomarker Correlations

Siontis, Konstantinos C, Abreau, Sean, Attia, Zachi I, Barrios, Joshua P, Dewland, Thomas A, Agarwal, Priyanka, Balasubramanyam, Aarthi, Li, Yunfan, Lester, Steven J, Masri, Ahmad, Wang, Andrew, Sehnert, Amy J, Edelberg, Jay M, Abraham, Theodore P, Friedman, Paul A, Olgin, Jeffrey E, Noseworthy, Peter A, Tison, Geoffrey H

application/pdf

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond

Khadija Sarwer, Saeeda Lashari, Nida Rafaqat, Maher, Abdul Raheem, Muneeb Ur Rehman, Syed Muhammad Iraj Abbas

electronic resource

View item

Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide

Willeford, Andrew, Enciso, Jorge Silva

application/pdf

This result is not displayed to guests.
Login for full access.

Ca2+ sensitivity changes in skinned myocardial fibers induced by myosin–actin crossbridge-independent sarcomere stretch: Role of N-domain of MyBP-C

Wang, Xutu ^{a, 1}, Kallish, Nathan ^a, Solaro, R. John ^b, Dong, Wen-Ji ^{a, c, ⁎}

Real-World Assessment of Mavacamten's Impact on Left Ventricular Systolic and Diastolic Functions in Obstructive Hypertrophic Cardiomyopathy: A 1-Year Single-Center Observational Study

Abood, Zaid ^a, Jan, M. Fuad ^{a, b}, Ashraf, Muddasir ^a, Hundal, Prabhjot ^a, Howard, Lauren ^a, Sanders, Heather ^a, Misicka, Amanda ^a, Ghafoor, Asad ^{a, b}, Jahangir, Arshad ^{a, b}, Galazka, Patrycja ^{a, b}, Tajik, A. Jamil ^{a, b, ⁎}

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Bryton J. Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen, Roberto Barriales‐Villa, Pablo Garcia‐Pavia, Iacopo Olivotto, Anjali T. Owens, Caroline J. Coats, Theodore P. Abraham, Scott D. Solomon, Martin S. Maron, Ahmad Masri

electronic resource

View item

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials

Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar

electronic resource

View item; View item

Mavacamten

Matthew W. Martinez, MD, Dewey Seto, BSBA, Michael Cheung, DHSc, Michele Coiro, MBA, Niki Patel, PharmD, Arnaud Bastien, MD, Jeffrey Lockman, PhD, Sonia Afsari, MD, Milind Y. Desai, MD, MBA

electronic resource

View item; View item

Kommentar zu den Leitlinien 2023 der ESC zum Management von Kardiomyopathien

Comments on the 2023 guidelines of the ESC on management of cardiomyopathies

Meder, Benjamin^{Aff1, IDs1218102400685w_cor1}, Eckardt, Lars^{Aff2, Aff8}, Falk, Volkmar, Klaassen, Sabine, Klingenheben, Thomas, Knebel, Fabian, Schulze-Bahr, Eric, Schulz-Menger, Jeanette

Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022

Goyal, Parveen Kumar^{Aff1, IDs40495024003515_cor1}, Sangwan, Kavita